IGATECH was founded in 2009 as a spin-off of the Institute of Applied Genomics. The company operates in the sequencing and bioinformatics sector and was the first NGS service provider in Italy.
The main activity of the company is to design, develop and supply methods in the field of DNA and RNA sequencing. We operate in total autonomy having over 300 square meters of laboratories equipped with various types of sequencers and robots for sample management.
“Our success in the market”
Our group can leverage highly qualified researchers who started working with NGS platforms when these were still in the early stage of their technological development. We have developed not only a great experience on a multitude of technologies and applications, but also a vast competence in project management, considering the possible risks but also the opportunities for new technological developments.
We are stimulated by the continuous research and implementation of new technologies to help basic and applied research achieve ambitious goals. To be successful, we apply an industrial approach to experimental processes.
Our services to basic and applied research offer the largest portfolio of solutions in every field: human, animal, plant, microbes. We can perform all sorts of analysis such as genetic, epigenetic, transcriptional, and single cell. Moreover, research groups rely on us also for ecology, biodiversity studies and the analysis of microbiomes.
For crop and animal production, we have set up a line of cutting-edge services in the field of agrigenomics with the aim of better exploiting genetic resources; the reconstruction of genomes and the large-scale analysis of diversity are the most important combination. Thanks to automation, we can process thousands of samples per week.
In the last years we have established multiple collaborations with biologics, gene therapies and regenerative medicine companies. The characterization of these products, previously impossible with normal laboratory assays, allows the evaluation of the safety profiles of these new generation drugs as well as to optimize the industrial and control processes associated with them.